"The Vaccine Integrity Project's goal was to perform a comprehensive review of the most recent published influenza, COVID-19, and RSV immunization data and to share that information with medical societies that were writing immunization guidelines and with the American public," Griffis said.
He noted that the project had provided findings during the course of the review to the American Academy of Pediatrics, American College of Obstetricians and Gynecologists, Infectious Diseases Society of America (IDSA), American Academy of Family Physicians, and American College of Physicians to inform their recommendations and pointed out that IDSA in particular had utilized and credited the project's review in formulating recommendations for vaccine use in immunocompromised persons.
What You Need to Know
The Vaccine Integrity Project conducted an independent assessment of more than 500 recent studies on COVID-19, RSV, and influenza vaccines—separate from HHS and ACIP—to provide a rigorous, unbiased synthesis of current evidence.
Reviewers found no new data that would support changes to existing ACIP COVID-19 vaccine recommendations, reinforcing confidence in the safety and effectiveness of the vaccines studied for the 2025–26 season.
The project supplied its findings to major medical societies and regional public health groups, several of which—including IDSA—used the review to inform their clinical guidance, underscoring the review’s influence during a period of shifting federal advisory processes.
"We have been in communication with the regional public health initiatives [eg, West Coast Health Alliance and the Northeast Public Health Collaborative, which formed to synthesize recommendations in response to changes at HHS and the ACIP] and have updated them on the project's works," Griffis added.
The lead author of the review, Jake Scott, MD, of the Division of Infectious Diseases & Geographic Medicine at Stanford University School of Medicine in California, explained to Contagion that although the review conveyed evidence of vaccine safety and effectiveness, it did not offer recommendations.
"We intentionally limited our scope to the data rather than policy recommendations or coverage decisions," Scott said. "The evidence we synthesized supports the continued safety and effectiveness of these vaccines in the populations studied, but translating that evidence into specific recommendations involves considerations beyond our review's scope.
"Our goal was to provide clinicians and health professionals with an independent, rigorous synthesis of recent vaccine data during a time of transition in advisory processes," Scott recounted. "We hope this evidence base helps inform clinical decision-making as we approach the respiratory virus season."
References
1. Scott J, Abers MS, Marwah HK, et al. Updated evidence for COVID-19, RSV, and influenza vaccines for 2025-2026. N Engl J Med. Published online October 29, 2025. doi:10.1056/NEJMsa2514268
3. Griffis K. Why I left my job leading public health messaging for the CDC. Washington Post. March 25, 2025. https://www.washingtonpost.com/opinions/2025/03/25/rfk-hhs-cdc-public-health-misinformation-spread/